ERBB2 and cancer: Because approximately 40% of patients with HR-positive, HER2-negative breast cancer also have the PIK3CA mutation, alpelisib–fulvestrant is an effective therapeutic combination for targeted therapy, especially for cancers with endocrine resistance [22].